Trial abstract · §3
PETRE-PH1B — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Safety, tolerability and pharmacokinetics of multiple ascending doses | Weight reduction of approximately 8.6 % at 16 weeks in a phase 1b setting | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Petrelintide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 21.0 | 9.0 | Phase 1b (highest dose) |
| Vomiting | 7.0 | 2.0 | Phase 1b |
| Injection-site reaction | 11.0 | 4.0 | Phase 1b |
| Discontinuation for adverse events | 4.0 | 2.0 | Phase 1b |
Compound Evidence Institute · CEI-TR-0064/3 · https://compoundevidence.com/trials/petre-ph1b/results/ · retrieved 30 July 2026